Janux Therapeutics (JANX) Receivables - Accured (2021 - 2025)
Historic Receivables - Accured for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to $6.3 million.
- Janux Therapeutics' Receivables - Accured rose 4000.0% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 4000.0%. This contributed to the annual value of $5.4 million for FY2024, which is 14545.45% up from last year.
- As of Q3 2025, Janux Therapeutics' Receivables - Accured stood at $6.3 million, which was up 4000.0% from $5.7 million recorded in Q2 2025.
- In the past 5 years, Janux Therapeutics' Receivables - Accured ranged from a high of $28.0 million in Q3 2021 and a low of $3000.0 during Q2 2021
- Over the past 5 years, Janux Therapeutics' median Receivables - Accured value was $2.0 million (recorded in 2023), while the average stood at $4.0 million.
- Examining YoY changes over the last 5 years, Janux Therapeutics' Receivables - Accured showed a top increase of 990000.0% in 2022 and a maximum decrease of 9892.86% in 2022.
- Quarter analysis of 5 years shows Janux Therapeutics' Receivables - Accured stood at $200000.0 in 2021, then soared by 250.0% to $700000.0 in 2022, then skyrocketed by 214.29% to $2.2 million in 2023, then skyrocketed by 145.45% to $5.4 million in 2024, then grew by 16.67% to $6.3 million in 2025.
- Its Receivables - Accured was $6.3 million in Q3 2025, compared to $5.7 million in Q2 2025 and $5.6 million in Q1 2025.